A total of 21 patients, out of 908 individuals treated with anti-PD1/PDL1 (in conjunction with an anti-CTLA-4 agent in 40 cases), experienced systemic rheumatologic irAEs, including SjS (0.3%). Here, CTLA4 is linked to Schwartz-Jampel syndrome.